CA2968926C - Compositions and methods for delivering a bio-active agent or bio-active agents - Google Patents
Compositions and methods for delivering a bio-active agent or bio-active agents Download PDFInfo
- Publication number
- CA2968926C CA2968926C CA2968926A CA2968926A CA2968926C CA 2968926 C CA2968926 C CA 2968926C CA 2968926 A CA2968926 A CA 2968926A CA 2968926 A CA2968926 A CA 2968926A CA 2968926 C CA2968926 C CA 2968926C
- Authority
- CA
- Canada
- Prior art keywords
- active agent
- composition
- weight
- kaolin
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462084387P | 2014-11-25 | 2014-11-25 | |
| US62/084,387 | 2014-11-25 | ||
| PCT/IB2015/002345 WO2016083891A1 (en) | 2014-11-25 | 2015-11-25 | Compositions and methods for delivering a bio-active agent or bio-active agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2968926A1 CA2968926A1 (en) | 2016-06-02 |
| CA2968926C true CA2968926C (en) | 2023-01-17 |
Family
ID=56073684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2968926A Active CA2968926C (en) | 2014-11-25 | 2015-11-25 | Compositions and methods for delivering a bio-active agent or bio-active agents |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10471070B2 (https=) |
| EP (1) | EP3223793B1 (https=) |
| JP (1) | JP6686023B2 (https=) |
| KR (1) | KR102511830B1 (https=) |
| CN (1) | CN107645951B (https=) |
| CA (1) | CA2968926C (https=) |
| WO (1) | WO2016083891A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018220444A2 (en) * | 2017-05-30 | 2018-12-06 | Eximore Ltd. | Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide |
| CN111110636B (zh) * | 2018-11-01 | 2022-09-27 | 复旦大学附属眼耳鼻喉科医院 | 使用纳米介孔氧化硅高效负载及缓释抗青光眼药物 |
| US12447045B2 (en) | 2019-10-02 | 2025-10-21 | Segal Innovations LLC | Bio-adhesive dissolving compounds and device |
| US11207267B2 (en) | 2019-10-02 | 2021-12-28 | Segal Innovations LLC | Bio-adhesive dissolving compounds and device |
| MX2022006803A (es) * | 2019-12-04 | 2022-09-19 | Restore Vision Llc | Formulaciones oftalmicas para el tratamiento de la presbicia. |
| WO2022096931A2 (en) * | 2020-11-09 | 2022-05-12 | Eximore Ltd. | Punctal plugs containing micelle-encapsulated ophthalmic pharmaceuticals and methods for making thereof |
| EP4346720A4 (en) | 2021-05-28 | 2025-01-01 | Sight Sciences, Inc. | INTRAOCULAR DEVICES, SYSTEMS AND METHODS |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2534580A1 (fr) | 1982-10-13 | 1984-04-20 | Synthelabo | Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent |
| US5151444B1 (en) | 1987-09-18 | 1999-07-06 | R Tech Ueno Ltd | Ocular hypotensive agents |
| DE1300150T1 (de) | 1988-09-06 | 2003-09-18 | Pharmacia Ab, Stockholm | Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck |
| US5296504A (en) | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| US5510383A (en) | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| JP4000505B2 (ja) | 1999-12-01 | 2007-10-31 | 第一三共株式会社 | 緑内障を治療するための併用剤 |
| US20020172693A1 (en) * | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| EP2004172B1 (en) * | 2006-03-31 | 2019-03-13 | Mati Therapeutics Inc. | Drug delivery structures and compositions for nasolacrimal system |
| CN101505695A (zh) * | 2006-06-21 | 2009-08-12 | 庄臣及庄臣视力保护公司 | 用于递送活性试剂的泪点塞 |
| UY30883A1 (es) | 2007-01-31 | 2008-05-31 | Alcon Res | Tapones punctales y metodos de liberacion de agentes terapeuticos |
| AU2008300013A1 (en) | 2007-09-07 | 2009-03-19 | Qlt Inc. | Drug cores for sustained release of therapeutic agents |
| EP2320972B1 (en) * | 2008-05-08 | 2020-07-01 | MiniPumps, LLC | Implantable drug-delivery devices |
| US9095404B2 (en) * | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| EP2303184A4 (en) * | 2008-06-24 | 2013-06-19 | Quadra Logic Tech Inc | COMBINATION TREATMENT OF GREEN STAR |
| US20100158980A1 (en) * | 2008-12-18 | 2010-06-24 | Casey Kopczynski | Drug delivery devices for delivery of therapeutic agents |
| CA2798084A1 (en) * | 2010-05-17 | 2011-11-24 | Aerie Pharmaceuticals, Inc. | Drug delivery devices for delivery of ocular therapeutic agents |
| US20120238994A1 (en) * | 2010-12-22 | 2012-09-20 | Martin Nazzaro | Two-piece injectable drug delivery device with heat-cured seal |
| US20120276186A1 (en) | 2011-04-29 | 2012-11-01 | Ghebremeskel Alazar N | Sustained release latanoprost implant |
| ES2727203T3 (es) * | 2011-08-29 | 2019-10-14 | Mati Therapeutics Inc | Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular |
| NZ742005A (en) * | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| JP2016515583A (ja) * | 2013-03-27 | 2016-05-30 | フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． | オキュラー・インサートおよびその使用方法 |
-
2015
- 2015-11-25 WO PCT/IB2015/002345 patent/WO2016083891A1/en not_active Ceased
- 2015-11-25 CN CN201580074504.0A patent/CN107645951B/zh active Active
- 2015-11-25 US US15/529,474 patent/US10471070B2/en active Active
- 2015-11-25 EP EP15862306.6A patent/EP3223793B1/en active Active
- 2015-11-25 CA CA2968926A patent/CA2968926C/en active Active
- 2015-11-25 JP JP2017528854A patent/JP6686023B2/ja not_active Expired - Fee Related
- 2015-11-25 KR KR1020177017184A patent/KR102511830B1/ko active Active
-
2019
- 2019-08-05 US US16/531,665 patent/US20200093834A1/en not_active Abandoned
-
2020
- 2020-10-23 US US17/078,534 patent/US12318394B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016083891A1 (en) | 2016-06-02 |
| EP3223793A4 (en) | 2018-08-01 |
| JP6686023B2 (ja) | 2020-04-22 |
| EP3223793A1 (en) | 2017-10-04 |
| CN107645951B (zh) | 2021-05-04 |
| US20210137942A1 (en) | 2021-05-13 |
| KR102511830B1 (ko) | 2023-03-17 |
| CN107645951A (zh) | 2018-01-30 |
| CA2968926A1 (en) | 2016-06-02 |
| KR20170103776A (ko) | 2017-09-13 |
| US12318394B2 (en) | 2025-06-03 |
| US10471070B2 (en) | 2019-11-12 |
| EP3223793B1 (en) | 2023-06-28 |
| US20170266200A1 (en) | 2017-09-21 |
| US20200093834A1 (en) | 2020-03-26 |
| JP2017535592A (ja) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2968926C (en) | Compositions and methods for delivering a bio-active agent or bio-active agents | |
| US20050214372A1 (en) | Stable pharmaceutical composition comprising an acid labile drug | |
| KR100396171B1 (ko) | 염산 파수딜의 경구 서방성 제제 | |
| CA2495463C (en) | Extended release composition containing tramadol | |
| JP7682226B2 (ja) | ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法 | |
| JP2009512645A (ja) | 親油性かつ／または低皮膚浸透性の活性物質を投与するための経皮治療システム | |
| US20190216825A1 (en) | Extended-release drug delivery compositions | |
| WO2002078604A2 (en) | Transdermal delivery of bioactive material | |
| AU2006298693A1 (en) | Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof | |
| KR20200004816A (ko) | 흡입용 건조 분말 제제를 위한 신규 담체 입자 | |
| EP3582760A1 (en) | Pharmaceutical composition comprising an antiemetic agent and method for the preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201019 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260109 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260318 |